2026-06-30--12-312026Q20002070534false00020705342026-01-012026-06-300002070534us-gaap:PreferredStockMember2026-06-122026-06-120002070534us-gaap:CommonStockMember2026-06-122026-06-120002070534us-gaap:PreferredStockMember2026-01-012026-06-300002070534us-gaap:RetainedEarningsMember2026-06-300002070534us-gaap:AdditionalPaidInCapitalMember2026-06-300002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-300002070534us-gaap:RetainedEarningsMember2025-12-310002070534us-gaap:AdditionalPaidInCapitalMember2025-12-310002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-310002070534us-gaap:RetainedEarningsMember2025-06-300002070534us-gaap:AdditionalPaidInCapitalMember2025-06-300002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-300002070534us-gaap:RetainedEarningsMember2024-12-310002070534us-gaap:AdditionalPaidInCapitalMember2024-12-310002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310002070534us-gaap:PreferredStockMember2026-06-300002070534us-gaap:CommonStockMember2026-06-300002070534us-gaap:CommonStockMember2025-12-310002070534us-gaap:CommonStockMember2025-06-300002070534us-gaap:CommonStockMember2024-12-310002070534us-gaap:SubsequentEventMember2026-09-242026-09-240002070534slbt:CorporateCustomersMemberslbt:ExosomeConcentrateMember2026-01-012026-06-300002070534slbt:CorporateCustomersMember2026-01-012026-06-300002070534slbt:RetailCustomersMemberslbt:SkinCareProductsMember2025-01-012025-06-300002070534slbt:RetailCustomersMemberslbt:HairCareProductsMember2025-01-012025-06-300002070534slbt:RetailCustomersMemberslbt:ExosomeConcentrateMember2025-01-012025-06-300002070534slbt:CorporateCustomersMemberslbt:SkinCareProductsMember2025-01-012025-06-300002070534slbt:CorporateCustomersMemberslbt:HairCareProductsMember2025-01-012025-06-300002070534slbt:CorporateCustomersMemberslbt:ExosomeConcentrateMember2025-01-012025-06-300002070534slbt:SkinCareProductsMember2025-01-012025-06-300002070534slbt:RetailCustomersMember2025-01-012025-06-300002070534slbt:HairCareProductsMember2025-01-012025-06-300002070534slbt:ExosomeConcentrateMember2025-01-012025-06-300002070534slbt:CorporateCustomersMember2025-01-012025-06-300002070534us-gaap:NonrelatedPartyMember2026-01-012026-06-300002070534slbt:NewProductPipelineMember2026-01-012026-06-300002070534slbt:JiYanBiomedicalCo.LtdMemberus-gaap:RelatedPartyMember2025-01-012025-06-300002070534us-gaap:RelatedPartyMember2025-01-012025-06-300002070534us-gaap:NonrelatedPartyMember2025-01-012025-06-300002070534slbt:NewProductPipelineMember2025-01-012025-06-300002070534slbt:SlBioLtdMemberus-gaap:SubsequentEventMember2026-07-012026-07-310002070534us-gaap:RelatedPartyMember2026-01-012026-06-300002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:PaymentOfResearchAndDevelopmentCostsMemberus-gaap:RelatedPartyMember2025-01-012025-06-300002070534slbt:SlLinkCo.Ltd.Memberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2024-06-202024-06-200002070534us-gaap:OfficeEquipmentMember2026-06-300002070534us-gaap:MachineryAndEquipmentMember2026-06-300002070534us-gaap:LeaseholdImprovementsMember2026-06-300002070534us-gaap:OfficeEquipmentMember2025-12-310002070534us-gaap:MachineryAndEquipmentMember2025-12-310002070534us-gaap:LeaseholdImprovementsMember2025-12-310002070534slbt:Mr.WangMemberus-gaap:RelatedPartyMember2026-06-300002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-06-300002070534us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-06-300002070534us-gaap:RetainedEarningsMember2026-01-012026-06-300002070534us-gaap:RetainedEarningsMember2025-01-012025-06-300002070534slbt:SlBioTaiwanMember2026-06-300002070534slbt:SlBioLtdMember2026-06-300002070534slbt:HorizonSpaceAcquisitionIiCorpMember2026-06-300002070534us-gaap:OperatingSegmentsMemberslbt:GdtCellTherapyProductsSegmentMember2026-01-012026-06-300002070534us-gaap:OperatingSegmentsMemberslbt:Cd19ArmedTProductsSegmentMember2026-01-012026-06-300002070534slbt:CorporateAndReconcilingItemsMember2026-01-012026-06-300002070534us-gaap:OperatingSegmentsMemberslbt:GdtCellTherapyProductsSegmentMember2025-01-012025-06-300002070534us-gaap:OperatingSegmentsMemberslbt:Cd19ArmedTProductsSegmentMember2025-01-012025-06-300002070534slbt:CorporateAndReconcilingItemsMember2025-01-012025-06-3000020705342025-01-012025-12-310002070534slbt:HorizonSpaceAcquisitionIiCorpMember2026-06-300002070534slbt:SlBioLtdMember2026-05-210002070534slbt:SlBioLtdMember2026-05-140002070534us-gaap:OperatingSegmentsMemberslbt:ExosomeProductsSegmentMember2026-01-012026-06-300002070534us-gaap:OperatingSegmentsMemberslbt:ExosomeProductsSegmentMember2025-01-012025-06-300002070534us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberslbt:VendorMember2026-01-012026-06-300002070534slbt:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-06-300002070534slbt:CustomeraMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2026-01-012026-06-300002070534us-gaap:CostOfGoodsTotalMemberus-gaap:SupplierConcentrationRiskMemberslbt:VendorMember2025-01-012025-06-300002070534slbt:CustomerBMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2025-01-012025-06-300002070534slbt:HorizonSpaceAcquisitionIiCorpMember2026-06-120002070534slbt:HorizonSpaceAcquisitionIiCorpMember2026-06-1200020705342024-12-310002070534slbt:SlBioLtdMember2026-06-122026-06-120002070534us-gaap:OperatingSegmentsMemberslbt:ExosomeProductsSegmentMember2026-06-300002070534slbt:CorporateAndReconcilingItemsMember2026-06-300002070534us-gaap:OperatingSegmentsMemberslbt:ExosomeProductsSegmentMember2025-06-300002070534slbt:CorporateAndReconcilingItemsMember2025-06-300002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2024-06-202024-06-200002070534slbt:HexunBiosciencesCo.LtdMember2026-03-022026-03-020002070534slbt:HexunBiosciencesCo.LtdMember2025-12-112025-12-110002070534slbt:JiYanBiomedicalCo.LtdMemberus-gaap:RelatedPartyMember2025-04-082025-04-080002070534slbt:HorizonSpaceAcquisitionIiCorpMember2026-06-122026-06-120002070534us-gaap:AdditionalPaidInCapitalMember2026-01-012026-06-300002070534us-gaap:CommonStockMember2026-01-012026-06-300002070534us-gaap:SubsequentEventMember2027-01-010002070534us-gaap:SubsequentEventMember2026-09-240002070534slbt:SlBioLtdMember2026-01-012026-06-300002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:PancreaticCancerProductsMemberus-gaap:RelatedPartyMember2025-04-080002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:BrainCancerProductsMemberus-gaap:RelatedPartyMember2025-04-080002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2024-06-200002070534slbt:WangChingDongMemberslbt:CytoarmCoLtdMemberus-gaap:RelatedPartyMember2026-01-012026-06-300002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:ChiefTechnicalOfficerMember2026-01-012026-06-300002070534slbt:WangChingDongMemberslbt:CytoarmCoLtdMemberus-gaap:RelatedPartyMember2025-01-012025-12-310002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:ChiefTechnicalOfficerMember2025-01-012025-12-310002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2025-01-012025-12-310002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2026-01-012026-06-300002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2025-01-012025-06-300002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2026-06-300002070534slbt:CytoarmCoLtdMemberslbt:Cd19ArmedTProductsMemberus-gaap:RelatedPartyMember2025-12-3100020705342026-06-122026-06-1200020705342026-03-242026-03-240002070534slbt:JiYanBiomedicalCo.LtdMemberslbt:ChiefTechnicalOfficerMember2024-12-272024-12-270002070534slbt:JiYanBiomedicalCo.LtdMemberus-gaap:RelatedPartyMember2026-01-012026-06-300002070534slbt:JiYanBiomedicalCo.LtdMemberus-gaap:RelatedPartyMember2024-12-012024-12-310002070534slbt:SlBioLtdMember2026-06-1200020705342025-03-1800020705342026-03-2400020705342026-06-3000020705342025-06-3000020705342026-06-120002070534slbt:HexunBiosciencesCo.LtdMember2026-01-012026-06-300002070534us-gaap:AdditionalPaidInCapitalMember2025-01-012025-06-3000020705342025-01-012025-06-3000020705342025-12-31iso4217:USDxbrli:purexbrli:sharesslbt:agreementslbt:Voteiso4217:TWDiso4217:USDxbrli:shares

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

For the month of October 2026

​

Commission File Number: 001-43346

​

SL Science Holding Limited

(Translation of registrant’s name into English)

​

11th Floor,

No. 479 Chongyang Road,

Nangang District, Taipei, Taiwan R.O.C. 115010

+886-2-26516826

(Address of principal executive offices)

​

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

​

☒   Form 20-F       ☐ Form 40-F

​

​

​

​

EXPLANATORY NOTE

​

SL Science Holding Limited (the “Company”) is furnishing this Form 6-K to provide the Unaudited Interim Consolidated Financial Statements of the Company for the Six Months Ended June 30, 2026 and 2025 (the “Unaudited Financials”), which are furnished as Exhibit 99.1 hereto, and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, which are furnished as Exhibit 99.2 hereto.

​

On October 26, 2026, the Company issued a press release announcing the Unaudited Financials. A copy of the press release is furnished as Exhibit 99.3 hereto.

​

This Form 6-K is hereby incorporated by reference into the Company’s registration statements on Form S-8 (Registration No. 333-299394), to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

​

​

EXHIBIT INDEX

​

Exhibit
No.

  ​ ​ ​

Description

99.1

 

Unaudited Interim Consolidated Financial Statements for the Six Months Ended June 30, 2026 and 2025

99.2

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

99.3

 

Press Release

101.INS

 

Inline XBRL Instance Document.

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104

 

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

​

​

​

SIGNATURES

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

 

SL Science Holding Limited

 

 

 

Date: October 26, 2026

By:

/s/ William Wang

 

Name: 

William Wang

 

Title:

Chief Executive Officer

​


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

EX-99.1

EX-99.2

EX-99.3

EX-101.SCH

EX-101.CAL

EX-101.DEF

EX-101.LAB

EX-101.PRE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: R38.htm

IDEA: R39.htm

IDEA: R40.htm

IDEA: R41.htm

IDEA: R42.htm

IDEA: R43.htm

IDEA: R44.htm

IDEA: R45.htm

IDEA: R46.htm

IDEA: R47.htm

IDEA: R48.htm

IDEA: R49.htm

IDEA: R50.htm

IDEA: R51.htm

IDEA: R52.htm

IDEA: R53.htm

IDEA: R54.htm

IDEA: R55.htm

IDEA: R56.htm

IDEA: R57.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: slbt-20260630x6k_htm.xml